Clin Mol Hepatol.
2025 Jan;31(1):e98-e100. 10.3350/cmh.2024.0916.
Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
- Affiliations
-
- 1Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
- 2Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
- 3Department of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
- KMID: 2563472
- DOI: http://doi.org/10.3350/cmh.2024.0916
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
- Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
- Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
- Letter to the editor on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/ bevacizumab failure: A real-world study”
- Complete response in hepatocellular carcinoma with lymph node metastasis by combination therapy of atezolizumab and bevacizumab: a case report
